Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Baltimore, Maryland 21225


This first-in-human (FIH) study is a randomized, double-blinded, placebo-controlled, ascending dose study to investigate the safety, tolerability, and pharmacokinetics of XmAb7195 in adult healthy volunteers and in adult subjects with elevated IgE levels.


Inclusion Criteria: - Adult males and females 18 to 50 years of age - Parts 1 and 3: Healthy subjects with no clinically significant abnormality identified on medical or laboratory evaluation and no history of any clinically significant disorder, condition, or disease that would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion; - Part 2: Otherwise healthy male and female subjects with a history of allergic rhinitis and/or allergic conjunctivitis and/or atopic dermatitis with an elevated serum IgE - Subjects who are able and willing to give written informed consent; - Subjects who have the ability to complete all study assessments; - Subjects who are willing to forego other forms of experimental treatment during the study. Exclusion Criteria: - Subjects who have a clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, hematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, connective tissue diseases, or disorders (other than allergic rhinitis and/or conjunctivitis and/or atopic dermatitis in Part 2) that would pose a significant risk to subject safety or significantly interfere with the study evaluation, procedures, or completion - Subjects who are positive for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody and/or human immunodeficiency virus (HIV) Type I or Type II tests at Screening; - Subjects who do not agree to use medically acceptable methods of contraception (as defined in the protocol); - Subject is pregnant or breast feeding, or planning to become pregnant within 3 months of administration of XmAb7195; - Subjects who have used any investigational drug in any clinical trial within 8 weeks prior to admission (Day -1), or have used an experimental monoclonal antibody; - Subjects with prior exposure to a monoclonal antibody; - Subjects with a history of anaphylaxis; - Subjects who have received live vaccines ≤ 3 months from Screening;



Primary Contact:

Principal Investigator
Ronald Goldwater, MD
Parexel Baltimore Early Phase Clinical Unit

Backup Contact:


Location Contact:

Baltimore, Maryland 21225
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.